Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMCSXI4)

Drug Name	Elezanumab DMCSXI4
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Multiple sclerosis	DISB2WZI	8A40	Phase 2	[1]
Spinal cord injury	DISOR9PQ	ND51.2	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03737812) A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04295538) Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (ELASCI). U.S. National Institutes of Health.